Botox Company Hugel Sold to GS Group Consortium for 1.7 Trillion KRW

[Asia Economy Reporter Seo So-jeong] On the 25th, it was announced that the largest shareholder of Hugel has changed to a corporation formed by GS Group and a domestic private equity fund.

The corporation 'LIDAC' (Leguh Issuer Designated Activity Company), the largest shareholder of Hugel, signed a share transfer agreement involving a change of the largest shareholder with GS Group's multinational consortium (APHRODITE ACQUISITION HOLDINGS LLC).

The transfer price for a total of 6,156,932 shares (46.9% of the total issued shares), including 801,281 convertible shares, is approximately 1.7 trillion KRW.

GS Group's multinational consortium consists of an overseas SPC jointly invested by GS Group and domestic private equity fund IMM Investment, the Asia healthcare specialized investment fund CBC Group, and the Middle Eastern sovereign wealth fund Mubadala, with CBC Group as the largest shareholder.

A Hugel official stated, "Through organic synergy with GS Group, which is developing various bio businesses, IMM Investment, which has various successful cases in the healthcare field, as well as CBC Group, Asia's largest bio and healthcare specialized investment fund, and Mubadala, we will write a new history in the global medical aesthetic market."

Meanwhile, LIDAC acquired management rights of Hugel, which was then led by Dongyang H.C. as the largest shareholder, in 2017 by investing about 930 billion KRW.

This content was produced with the assistance of AI translation services.